The participating health insurance companies pursue the goal of concluding discount agreements with all suitable pharmaceutical companies in accordance with §§ 130a (8), 130c (1) SGB V on the active substance sarilumab. The contract is concluded within the framework of the open-house biologics procedure of the health insurances:

Individual negotiations on contract contents are not conducted, uniform conditions apply. The health insurance companies do not guarantee exclusivity for individual contract partners. The contract period is a maximum of 24 months starting from 1.1.2020. The contract ends at the latest on 31.12.2021, regardless of the date of conclusion of the contract. All further information can be found in the participation and contract documents. If the patent expires before 31.12.2021, the contract automatically ends at the end of the month of the patent expiration.

Joining this open house biologics procedure is possible at any time during the contract period.

Due to the existence of industrial property rights with regard to the contractual substance, the participation and contract documents are only made available to pharmaceutical companies that offer / market drugs or make them credible to TK, drugs to the subject substance within the To offer / sell the contract.

A contract is concluded with all pharmaceutical companies in the above sense who meet the requirements of Annex 4 to the contract (self-declaration for approval and the company) and confirm this by signing it.

This notice does not concern the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or antitrust law. In order to provide the widest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The procedure "Open procedure" used in this notice text according to Number IV.1.1) and the award criteria according to Number II.2.5) are due to the requirements of the Notice Form and have no further meaning. Hereby, as well as with the use of the medium "TED", no submission is subject to procurement regulations whose validity is not prescribed by law or public procurement regulations.